Electra Therapeutics Goes Public with Strong IPO Backed by HBM Healthcare

Electra Therapeutics, a clinical-stage biopharmaceutical company, commenced trading on Nasdaq under the ticker ETRA on September 18, 2026. HBM Healthcare Investments, a key investor, initially engaged with Electra in October 2025 with a USD 15 million investment during a Series C financing round valued at USD 183 million. HBM further invested USD 15 million in Electra's IPO, totaling its investment to USD 30 million.

The IPO priced at USD 15.00 per share, issuing 23.33 million shares and raising approximately USD 350 million in gross proceeds. Post-IPO, HBM holds a 3.9% stake in Electra, valued at USD 32.8 million based on the first day's closing price.

Electra is advancing its pipeline focusing on antibodies targeting signal regulatory proteins (SIRP). Its leading product, ipsoprubart, is in a Phase 2/3 trial for treating secondary hemophagocytic lymphohistiocytosis, a rare disorder.